Zahra Harrison
Adult Health · Colorado Springs, CONPI 1659529485
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,938 of the $10,836 with a category attached, or 82.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,846, 5.0 times the $772 reported in 2021. Among adult health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2K
- Johnson & Johnson$1K
- AbbVie$1K
- Gilead$845
- Sanofi$827
- Lilly USA, LLC$576
- plus $4K from 29 others
What the payments were for
- Travel & lodging$1,44113%
- Food & beverage$8,93882%
- Education$4574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 6 | $2,049 |
| Johnson & Johnson(2 entities) | 58 | $1,417 |
| AbbVie | 70 | $1,305 |
| Gilead | 30 | $845 |
| Sanofi | 25 | $827 |
| Lilly USA, LLC | 24 | $576 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $413 |
| Ardelyx, Inc. | 15 | $383 |
| Intercept Pharmaceuticals, Inc. | 13 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $297 |
| Bristol Myers Squibb | 17 | $296 |
| Regeneron Healthcare Solutions, Inc. | 8 | $265 |
| QOL Medical, LLC | 13 | $243 |
| Medtronic | 3 | $209 |
| Ferring Pharmaceuticals Inc. | 6 | $161 |
| Madrigal Pharmaceuticals | 6 | $156 |
| E.r. Squibb & Sons, L.L.C. | 2 | $151 |
| Celltrion USA Inc. | 7 | $122 |
| GSK | 2 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $98 |
| Pfizer | 2 | $87 |
| Nestle Healthcare Nutrition Inc. | 3 | $85 |
| Aimmune Therapeutics, Inc. | 3 | $76 |
| Redhill Biopharma Inc. | 3 | $57 |
| Ironwood Pharmaceuticals, Inc | 3 | $57 |
| Amgen | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Mylan Institutional Inc. | 1 | $25 |
| Merck | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,836 in reported general payments places this provider in the 95th percentile of 430 adult health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $371,895 |
| CreonLipase/Protease/Amylase | 35 | $143,986 |
| Humira PenAdalimumab | 13 | $86,029 |
| ZenpepLipase/Protease/Amylase | 14 | $60,266 |
| LinzessLinaclotide | 25 | $24,564 |
| TrulancePlecanatide | 12 | $9,173 |
| Mesalamine | 12 | $7,278 |
| MovantikNaloxegol Oxalate | 12 | $5,084 |
| Sucralfate | 44 | $4,546 |
| Esomeprazole Magnesium | 25 | $3,030 |
| Pantoprazole Sodium | 329 | $2,464 |
| Omeprazole | 90 | $1,111 |
| Lubiprostone | 13 | $974 |
| Famotidine | 105 | $946 |
| Colestipol Hcl | 16 | $883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,417 | $371,89513 claims |
| AbbVieCreon, Linzess | $1,305 | $168,55060 claims |
| Aimmune Therapeutics, Inc.Zenpep | $76 | $60,26614 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $413 | $9,17312 claims |
| Redhill Biopharma Inc.Movantik | $57 | $5,08412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 430 adult health providers in Colorado.
Other adult health in Colorado Springs
- Jamie ThompsonColorado Springs$31K
- Nicole KleinColorado Springs$6K
- Jennifer FlickingerColorado Springs$6K
- Deborah GriffinColorado Springs$5K
- Julie ReedColorado Springs$5K
- Tonia HowardColorado Springs$4K
- Elizabeth ArnoldColorado Springs$4K
- Stefanie EymarAurora$36K
- Toni StandleyDenver$23K
- Alexandra GravesAurora$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.